Candida tropicalis isolates often display reduced but persistent growth (trailing) over a broad fluconazole concentration range during EUCAST susceptibility testing. Whereas weak trailing (Ͻ25% of the positive growth control) is common and found not to impair fluconazole efficacy, we investigated if more pronounced trailing impacted treatment efficacy. Fluconazole efficacy against two weakly (Յ25% growth), two moderately (26% to 50% growth), and one heavily (Ͼ70% growth) trailing resistant isolate and one resistant (100% growth) isolate were investigated in vitro and in vivo (in a Galleria mellonella survival model and two nonlethal murine models). CDR1 expression levels and ERG11 sequences were characterized. The survival in fluconazole-treated G. mellonella was inversely correlated with the degree of trailing (71% to 9% survival in treatment groups). In mice, resistant and heavily trailing isolates responded poorly to fluconazole treatment. CDR1 expression was significantly higher in trailing and resistant isolates than in wild-type isolates (1.4-fold to 10-fold higher). All isolates exhibited ERG11 wild-type alleles. Heavily trailing isolates were less responsive to fluconazole in all in vivo models, indicating an impact on fluconazole efficacy. CDR1 upregulation may have contributed to the observed differences. Moderately trailing isolates responded less well to fluconazole in larvae only. This confirms clinical data suggesting fluconazole is effective against infections with such isolates in less severely ill patients and supports the current 50% growth endpoint for susceptibility testing. However, it is still unclear if the gradual loss of efficacy observed for moderately trailing isolates in the larva model may be a reason for concern in selected vulnerable patient populations.
reported that a proportion of several Candida species, and especially C. tropicalis, display growth inhibition of only 50% to 80% over a broad concentration range, defined as trailing growth, when using the 24-h EUCAST broth microdilution method (12) (13) (14) . However, the magnitude of the problem is largely unknown. Different definitions have been used with respect to proportional growth compared to the growth of a control (e.g., heavy trailers show Ͼ15% residual growth in one study but 25% to 49% in another) (12, 13) . Methodological issues, including pH value and incubation time, were shown to impact the degree of resistance (15) (16) (17) , and some authors report more trailing with the EUCAST method than with CLSI at 24 h (22% versus 1.7%) (18) . In Candida albicans, variable regulation of drug resistance genes was observed for isolates trailing by the 48-h CLSI method (19) , and various drug resistance mechanisms have been implicated in azole resistance in C. tropicalis (20) (21) (22) . Yet, it is unknown if trailing is related to the variable regulation of epigenetic traits or resistance mechanisms.
In our experience and among 81 Danish C. tropicalis blood isolates in the nationwide surveillance program from 2012 to 2015, most trailing C. tropicalis isolates displayed 10% to 25% residual growth. Severe trailing isolates with residual growth of approximately 50% and classified as nonsusceptible constituted a minority (7.4%) (14) . Difficulties in MIC determination persist particularly for isolates with trailing growth close to the 50% endpoint. Furthermore, it remains unclear if all trailing isolates are truly as susceptible in vivo as their nontrailing counterparts. The limited data from the CANDI-POP study demonstrated fluconazole treatment efficacy in a subset of patients with C. tropicalis displaying weak to strong trailing (13) . However, the very low 30-day mortality rate (ϳ10%) among the 21 initially fluconazole-treated patients in this analysis compared to the overall accumulative 30-day mortality (29% [15/51] ) of all included patients with C. tropicalis suggested that a selected (less severely ill) subset of patients may have been receiving fluconazole (13, 23) .
We were concerned if the conclusions drawn from earlier animal studies for isolates trailing only after 48 h might not apply to the minority of isolates with residual growth close to the 50% inhibition endpoint. We therefore further investigated the in vitro and in vivo efficacy of fluconazole against C. tropicalis isolates trailing after 24 h in EUCAST antifungal susceptibility testing. Furthermore, the sequences of ERG11 in the included isolates and the CDR1 expression levels were determined. The Galleria mellonella model was employed, as it has proven to be a suitable model to study C. tropicalis virulence and response to treatment, including to fluconazole (24) (25) (26) . The G. mellonella model has, however, not been fully validated for in vivo studies; thus, the isolates were further examined in a murine model of immunocompetent and immunocompromised animals.
(An abridged data set from the Galleria mellonella experiments was presented as a poster at the 7th TIMM conference in Lisbon in 2015.)
RESULTS
In vitro characteristics of the selected isolates. The weakly trailing isolates CT-WT1 and CT-WT2 were consistently categorized as susceptible by EUCAST and displayed mean trailing below 25% (Table 1 and Fig. 1 ). In contrast, the trailing isolates CT-TR1 and CT-TR2 were not clearly designated susceptible or resistant due to variations in endpoint reading. Two isolates were consistently categorized as resistant. One of these, the CT-TR-R isolate, displayed a reduced but persistent growth (Ͼ70% compared to the growth control) over the entire fluconazole concentration range, whereas CT-R displayed no trailing growth in the Ն4-mg/liter concentration range (Fig. 1 ). The degree of trailing was pH dependent and increased when lowering the pH, concomitantly with a 2-to 3-dilution-step increase of MIC values ( Table 2 ). An expression analysis of the ABC-transporter CDR1 revealed an approximately 10-fold upregulation in CT-R compared to that in both susceptible isolates CT-WT1 and CT-WT2, consistent with its categorization as a resistant isolate. Since the CDR1 expression data in CT-WT1 and CT-WT2 were similar, they were merged in Fig. 2 . A significant upregulation of CDR1 in isolates with moderate to high trailing (CT-TR1, CT-TR2, and CT-TR-R)
was observed compared to that in both CT-WT1 and CT-WT2 ( Fig. 2 ). All isolates were ERG11 wild types.
In vivo studies using the Galleria mellonella model. Mortality in the larva model was Ͼ90% by day 2 in all placebo groups and with a maximum of one larva still alive on day 5. A clear dose-dependent survival was observed, especially for isolates CT-WT1 and CT-TR1 ( Fig. 3 ). The survival rates for larvae challenged with CT-WT1 were Ͼ50% and Ͼ70% at day 5 in treatment groups receiving 5 and 20 mg/kg, respectively. In contrast, the survival was 40% for CT-TR1 and 10% to 20% for the remaining isolates in the 20 mg/kg groups. Given the pH-dependent trailing demonstrated in vitro, the pH values in hemolymph of uninfected versus infected larvae were investigated but were found to be similar and only slightly acidic (pH 6.6 versus 6.5).
In vivo studies using the immunocompetent murine model over 96h. The kidney burden was lower in mice treated with 35 mg/kg fluconazole than in untreated mice challenged with all isolates except CT-TR-R (P ϭ 0.56) ( Fig. 4A ). A dose-dependent reduction was observed, and 15 mg/kg was significantly better than no treatment for all isolates except CT-TR1 (P ϭ 0.08) ( Fig. 4B ). In isolate CT-WT2, the 5-mg/kg dose resulted in significant efficacy compared to untreated animals.
In vivo studies using neutropenic model over 24 h. Fluconazole 15 and 35 mg/kg were significantly more efficacious than no treatment for mice challenged with wildtype (CT-WT1 and CT-WT2) and moderate (CT-TR1 and CT-TR2) trailing. Only a treatment with 35 mg/kg was better than no treatment for the CT-TR-R isolate (P ϭ 0.04) ( Fig. 5 ). As expected, no treatment dose was effective for infection caused by the CT-R isolate ( Fig. 5 ).
DISCUSSION
A stepwise reduction in fluconazole efficacy was found for isolates with increasing degrees of trailing in the G. mellonella larva lethal candidiasis model, suggesting the observed differential susceptibility patterns were not solely an in vitro phenomenon. However, in immunocompetent mice, only the heavily trailing and fully resistant isolates failed to respond to fluconazole. We first speculated that the involvement of the murine immune system contributed to this discrepancy and repeated the experiments in the immunosuppressed mouse model. However, also in the case of the immune-suppressed model, only heavily trailing or the strictly resistant isolates were associated with a reduced response to fluconazole.
Murine models of invasive candidiasis are considered gold standards of in vivo animal candidiasis experimentation due to the similarity between humans and mice regarding internal anatomy, immune system, metabolism, and body temperature. However, several insect models have been of value in the testing of pathogenicity and treatment response to fungal infections. These models offer advantages in terms of low cost, ease of handling, an intact innate immune system, and a lack of ethical constraints (27) (28) (29) . The G. mellonella model is attractive due to its sufficient size for enabling The proportion of trailing in the 8 mg/liter concentration well compared to the antifungal-free growth control.
FIG 2
Expression levels of CDR1 in C. tropicalis. Expression levels were calculated as described in Materials and Methods and were normalized to ACT1 expression relative to merged data of CT-WT1 and CT-WT2 (CT-WT). ANOVA one-way statistics using merged data for CDR1 of both CT-WT1 and CT-WT2 (CT-WT) were employed as a reference. NS, not significant; *, P Ͻ 0.05; ***, P Ͻ 0.001; ****, P Ͻ 0.0001.
Astvad et al. Antimicrobial Agents and Chemotherapy precise challenge and treatment injections to be administered. Furthermore, the larval temperature tolerance enables experiments to be conducted at body temperature, which is important for the expression of some virulence traits (30) . Notably, previous Galleria experiments demonstrated that C. tropicalis infection causes tissue invasion and mortality with a fluconazole dose-and MIC-dependent response (24, 26) . We chose an upper dose of 20 mg/kg, which is well tolerated and gives a 24-h area under the curve (AUC) exposure of 400 mg·h/liter. This dosage corresponds to the human exposure during standard licensed dosing (31, 32) . The discrepant findings between the two in vivo models are intriguing given the substantial in vitro growth at higher fluconazole concentrations for trailing isolates. The in vitro trailing was potentiated with a decreasing pH. This is in contrast with results from a previous report (15) but raise questions as to whether fluconazole exhibited a reduced efficacy against trailing isolates in the larvae due to the slightly lower pH and whether drug efficacy may be affected when low pH foci are present. Due to ethical constraints, we were not able to apply a mortality endpoint to the murine experiments. It is possible that the lethal infection in the G. mellonella larvae exacerbated subtle differences in susceptibility, especially given that fluconazole was only administered once. In contrast, mice were administered daily doses initiated as early as 2 h postchallenge for a less severe infection followed by fungal load determinations. Infections caused by isolates with variable susceptibilities may be resolved due the intervention of immune responses. This type of response is important for efficient clearance of fungal pathogens, especially when exposed to fungistatic drugs (33, 34) . In immunocompetent mice, some individuals may partially clear the infection, hypothetically compensating a decrease in drug activity. However, the 24-h experiments using immunosuppressed mice did not consistently support this hypothesis. Nevertheless, our data suggest that trailing growth, at least when it is prominent (growth Ͼ50% above the endpoint reading), impacts drug treatment efficacy in all models.
This study has limitations. Even though the comprehensive molecular trailing phenotype remains uncharacterized, our results indicated that in the absence of involvement of target gene ERG11 mutations, fluconazole resistance in the CT-R isolate may be explained by the strong upregulation of CDR1. This also was the only isolate that was strictly azole resistant when adopting the 50% susceptibility testing endpoint. Of note, CDR1 expression distinguished low and high trailing isolates from the wild-type (WT) isolates. However, CDR1 expression was not related to the degree of trailing among the isolates (Fig. 2) ; therefore, we speculate that other mechanisms may play in concert (e.g., ERG11 and/or MDR1 upregulation) (20) (21) (22) . If it is mediated by efflux pump upregulation or another inducible mechanism, a 24-h murine model experiment may not be appropriate to detect resistance dependent on induction. Another potential caveat was that concomitant administration of ibuprofen was mandatory during murine experimentation. Ibuprofen has been shown to potentiate the in vivo activity of (35) . When retesting the trailing isolates in the neutropenic 24-h model without ibuprofen, fluconazole efficacy remained unchanged (data not shown).
In conclusion, the undertaken in vivo experiments yielded differential results dependent on the type of animal model. In the lethal Galleria model, fluconazole efficacy was inversely correlated with the degree of early 24-h trailing, whereas no lack of fluconazole efficacy was observed in the nonlethal murine models except for isolates with heavy trailing (Ͼ50% growth compared to that of the control). The data presented here indicate that both the degree of trailing and type of in vivo model are critical for predicting fluconazole treatment failure. Until further data are available, heavily trailing isolates should be regarded as clinically resistant to fluconazole, whereas lower degrees of trailing, depending on the model used, appear to have little or no impact on fluconazole efficacy. Thus, our findings per se support the use of a 50% cutoff as the endpoint for susceptibility categorization, at least in the nonseverely ill population, in agreement with previously published reports (5, 13) . However, the findings that CDR1 expression is upregulated in trailing isolates and that fluconazole efficacy is lower in the lethal Galleria model suggest that caution may be warranted when contemplating fluconazole step-down treatment for severe infections, especially in fragile or immunocompromised patients. This concern is supported by a recent study documenting fluconazole failure in the Galleria model of fluconazole trailing/tolerant C. albicans isolates from patients with persistent but not resolving candidemia (36) . Further characterizations of the mechanisms behind trailing in C. tropicalis and the potential implication in severe infections are warranted. Isolates. Six clinical isolates of C. tropicalis were selected among stored isolates to cover a range of azole EUCAST susceptibility phenotypes. The isolates included were CT-WT1 and CT-WT2 with weak trailing (Ͻ25% mean trailing growth), CT-TR1 and CT-TR2 with moderate trailing (26% to 50% mean trailing), and CT-TR-R with heavy trailing (Ͼ70% of mean trailing) resistance, and finally one resistant (nontrailing) isolate, CT-R, displaying uninhibited (100%) growth at concentrations of Ն4 mg/liter. Isolates were grown on CHROMagar (CHROMagar Co., Paris, France) for purity control and subcultured on Sabouraud dextrose agar (pH 4) (SSI Diagnostika, Hillerød, Denmark) at 35°C for 24 to 48 h prior to inoculation.
MATERIALS AND METHODS

Ethics
In vitro susceptibility testing. EUCAST MICs for fluconazole (Sigma-Aldrich, final drug concentration range of 0.125 to 16 mg/liter) were determined according to the E.DEF 7.3 (10) . The degree of trailing was determined as the percentage growth in wells with concentrations above the MIC compared to the growth control (background optical density [OD] subtracted). For isolates with an MIC of Ͼ16 mg/liter due to a trailing phenotype (CT-TR-R and occasionally CT-TR2), the percentage of trailing was determined for wells with concentrations at or above the susceptibility breakpoint of 2 mg/liter. The presented EUCAST MICs and trailing are mean results from seven tests on different days and batches of susceptibility plates. Finally, the effect of medium pH was examined using RPMI 1640 medium (Sigma-Aldrich) buffered by 0.1 M MOPS (morpholinepropanesulfonic acid) at pH 4.5, 6, and 7.0 using either HCl or NaOH.
Reverse transcription-quantitative PCR. Total RNA was extracted with a phenol-chloroform-lithium chloride procedure as previously described (37) . Biological triplicates from strains were prepared by growing the strains in 10 ml of yeast extract-peptone-dextrose (YEPD) medium until mid-exponentialgrowth phase (1.5 ϫ 10 7 cells/ml). Contaminating genomic DNA was removed by DNase treatment (DNA free; Ambion). The expression of CDR1 was quantitatively determined by quantitative real-time reverse transcription-PCR in a StepOne real-time PCR system (Applied Biosystems). The expression levels were normalized to ACT1 expression. Changes (n-fold) in gene expression relative to that of both strains CT-WT1 and CT-WT2 were determined from ACT1-normalized expression levels. The primers and probes used for this assay for CDR1 were CDR1F, GAGGTGTTTCTGGTGGTGAA; CtCDR1R, GCAGCATCCAAACCTC TAGT; and CDR1P, TGCTGAAGCATCCTTAAGTGGTGCT; and for ACT1 were ACT1F, CTCCTTGCCACACGGT ATTT; ACT1R, GGTGGTGGAGAAAGTGTAACC; and ACT1P, TGGCTGGTAGAGACTTGACCGACT. The primers used as TaqMan probes were labeled with 6-carboxyfluorescein (6-FAM) at the 5= end and with tetramethylrhodamine (TAMRA) at the 3= end. ERG11 sequencing. DNA was extracted from pure cultures using the NucliSENS easyMag (bio Mérieux) according to the manufacturer's instructions. The ERG11 gene was amplified in duplicates by conventional PCR with 40 cycles at an annealing temperature of 58°C, including an initial denaturation at 94°C and subsequent 72°C extension for 60 s. The primers used are listed in Table S1 in the Fluconazole Efficacy against Trailing in C. tropicalis Antimicrobial Agents and Chemotherapy supplemental material. All PCR products were sequenced by Macrogen, Holland, and compared to the ERG11 wild-type sequence from C. tropicalis reference strain ATCC 750 (GenBank accession M23673). Galleria mellonella model. Sixth-instar G. mellonella larvae (HPreptiles, Copenhagen, Denmark) were used, stored, weighted, and washed as previously described (32) . The mean weight of treatment groups was used for antifungal drug dosing. An individual experiment consisted of 15 larvae/treatment group (phosphate-buffered saline [PBS] and fluconazole 1, 5, and 20 mg/kg larvae) for all isolates (except CT-WT2, which was acquired later and only included in the murine experiments). Inocula previously determined to achieve an infection causing 100% mortality in PBS-treated larvae within 3 days were used. Yeast suspensions were prepared from Sabouraud agar by adding 24-h colonies to PBS (SSI Diagnostika, Hillerød, Denmark) with 20 mg/liter ampicillin (Pentrexyl; Bristol-Meyers Squibb, Virum, Denmark) for a final concentration between 0.5 ϫ 10 8 and 1 ϫ 10 8 CFU/ml. The concentrations were controlled by the spot technique (38) . Larvae were inoculated in the last left proleg with 10 l of yeast suspension (500-l Hamilton syringe with a PB600-1 Repeating Dispenser). After 28 Ϯ 3 min, the larvae received 10 l of control (PBS) or fluconazole treatment (1, 5, or 20 mg/kg larvae) prepared by diluting fluconazole (2 mg/ml for intravenous use; Fresenius Kabi) with sterile isotonic NaCl (B. Braun Melsungen AG, Melsungen, Germany) in the last right proleg. Control groups received fluconazole 20 mg/kg, PBS, NaCl, or PBS and NaCl to check for excessive death by any one agent or dual injections. For the final analyses, the results from three individual experiments were pooled (45 larvae/group). Only experiments with similar degrees of mortality in the PBS group (Ն14 larvae on the third day) were included. Mortality in the unchallenged control larvae never exceeded the predetermined limit of 15%.
To assess if the pH of the infected and noninfected larvae were different and might influence the degree of trailing in infection, the pH values of hemolymph from larvae without infection (pooled hemolymph from 20 larvae [275 to 325 mg/larva]) and early and late infection were measured (PHM 92; Radiometer Copenhagen, Denmark). For the early and late infection, larvae were inoculated with 10 l of a suspension of 6.5 ϫ 10 6 CFU/ml of CT-TR2, followed 30 min later with 10 l of fluconazole 20 mg/kg. The hemolymph was pooled from 20 larvae sacrificed 1 h posttreatment (for early infection) and from the 13 surviving of 30 infected larvae 22 h posttreatment (for late lethal infection).
Murine models. (i) Mice. NMRI mice (weight, 26 to 30 g; Taconic, Lille Skensved, Denmark) were used throughout the study. Groups of 3 to 4 mice were used for the virulence studies and of 6 to 7 mice for treatment groups. Ibuprofen 30 mg/kg bodyweight (Nurofen Junior 20 mg/ml; Reckitt Benckiser Deutschland GmbH, Germany) was administered once daily to minimize discomfort and pain (per requirement).
(ii) Immunocompetent model. On the basis of a prior virulence study (not shown), an inoculum (Ϸ1 ϫ 10 6 to 5 ϫ 10 6 CFU/mouse) resulting in a nonlethal sustained kidney infection was chosen for each of the five included C. tropicalis isolates (CT-WT1, CT-WT2, CT-TR1, CT-TR2, and CT-TR-R). On day 0, groups of mice were inoculated in the lateral tail veins with 200 l of Candida suspension. Treatment was administered intraperitoneally once daily (starting 2 h postinoculation) for four doses of 0.5 ml vehicle (NaCl) or fluconazole 35 mg/kg (2 mg/liter diluted in sterile saline; Fresenius Kabi). Mice were humanly sacrificed on day 4 (after 96 h of treatment), and the kidneys were harvested. For isolates CT-WT1, CT-WT2, CT-TR1, and CT-TR2, a second similar experiment was conducted with vehicle and treatment groups of 1, 5, and 15 mg/kg fluconazole. Mice displaying discomfort or inanition during the study were sacrificed by cervical dislocation. The actual inoculum was slightly higher than expected for isolate CT-WT2 (7.0 ϫ 10 6 CFU/ml). Two mice infected with this isolate were euthanized (one in the vehicle group on day 1 and one in the 1 mg/kg fluconazole [FLC1] group on day 2), and the resulting CFU counts were excluded from subsequent analyses. The remaining inocula were 2.2 ϫ 10 6 to 5.5 ϫ 10 6 CFU/ml.
(iii) Immunosuppression model. For this model, mice received two doses of cyclophosphamide (Sendoxan; Baxter) intravenously (200 mg/kg on day Ϫ4 and 100 mg/kg on day Ϫ1), yielding them neutropenic for the duration of the experiment (33, 39, 40) . Virulence studies were conducted to determine an appropriate inoculum of each of the six included C. tropicalis isolates (CT-WT1, CT-WT2, CT-TR1, CT-TR2, CT-TR-R, and CT-R). No inoculum was determined to enable a sustained nonlethal infection over 48 h; however, approximately 0.5 ϫ 10 5 to 1 ϫ 10 5 CFU/ml could be used over 24 h. Mice were inoculated with 200 l of yeast suspension intravenously and then 2 h later with 0.5 ml intraperitoneally of vehicle (NaCl) or fluconazole diluted to concentrations corresponding to 5, 15, or 35 mg/kg. Mice were sacrificed 24 h posttreatment.
For all experiments, the kidneys were aseptically harvested and frozen pairwise at Ϫ80°C. After thawing, they were homogenized by bead beating with two stainless steel beads in a Tissue Lyser II (Qiagen, Denmark) for 2 min at a frequency of 30/s after the addition of 1 ml of sterile water, and were serially diluted for CFU determination using the spot technique. One pair of kidneys was lost during transport between facilities prior to CFU determination (CT-WT2, fluconazole [FLC] 15 mg/kg, ibuprofen treated) and was not available for analysis.
Statistics. (i) Galleria mellonella. For individual isolates, the treatment effect was assessed with a log rank test.
(ii) Mouse models. CFU counts of individual isolates were compared between control and treatment groups by using the Mann-Whitney U test or Kruskal-Wallis (where appropriate) test with Dunn's multiple-comparison test.
(iii) CDR1 expression. Merged CT-WT1 and CT-WT2 data were compared to other expression data using a one-way analysis of variance (ANOVA) with a Dunnett's multiple-comparison test. All statistical calculations were performed using GraphPad Prism 6.07 (GraphPad Software, La Jolla, CA, USA). For all analyses, a P value of Ͻ0.05 was considered significant.
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